In our efforts to develop new approaches to treat and prevent human vascular diseases, we report herein our results on the proliferation and migration of human smooth muscles cells (SMCs) and endothelial cells (ECs) using epigallocatechin-3-gallate conjugated gold nanoparticles (EGCg-AuNPs) as possible alternatives to drug coated stents. Detailed in vitro stability studies of EGCg-AuNPs in various biological fluids, affinity and selectivity towards SMCs and ECs have been investigated. The EGCg-AuNPs showed selective inhibitory efficacy toward the migration of SMCs. However, the endothelial cells remained unaffected under similar experimental conditions. The cellular internalization studies have indicated that EGCg-AuNPs internalize into the SMCs and ECs within short periods of time through laminin receptor mediated endocytosis mode. Favorable toxicity profiles and selective affinity toward SMCs and ECs suggest that EGCg-AuNPs may provide attractive alternatives to drug coated stents and therefore offer new therapeutic approaches in treating cardiovascular diseases.
TCN006, a formulation of (R)-3-Hydroxybutyrate glycerides, is a promising ingredient for enhancing ketone intake of humans. Ketones have been shown to have beneficial effects on human health. To be used by humans, TCN006 must be determined safe in appropriately designed safety studies. The results of a bacterial reverse mutation assay, an in vitro mammalian micronucleus study, and 14-and 90-day repeat dose toxicity studies in rats are reported herein. In the 14- and 90-day studies, male and female Wistar rats had free access to drinking water containing 0, 75,000, 125,000 or 200,000 ppm TCN006 for 92 and 93 days, respectively. TCN006 tested negative for genotoxicity and the no observed adverse effect level (NOAEL) for toxicity in the 14- and 90-day studies was 200,000 ppm, the highest dose administered. In the longer term study, the mean overall daily intake of TCN006 in the 200,000 ppm groups was 14,027.9 mg/kg bw/day for males and 20,507.0 mg/kg bw/day for females. At this concentration, palatability of water was likely affected, which led to a decrease in water consumption in both males and females compared to respective controls. This had no effect on the health of the animals. Although the rats were administered very high levels of (R)-3-Hydroxybutyrate glycerides, there were no signs of ketoacidosis.
Efficient glucose uptake by peripheral tissue is important for individuals who desire to maintain optimal wellbeing. Various methods to regulate postprandial blood glucose have been reported in the research literature, however, few have examined the effect of ketone esters on blood glucose levels. The present study evaluated blood glucose following the administration of an oral glucose tolerance test, with and without ketone esters delivered at two different dosages, in a sample of healthy Sprague-Dawley rats. We hypothesized that the ketone esters would lower the glucose Area Under the Curve (AUC) in response to oral glucose ingestion, in a dose dependent manner. A single dose ketone monoester (Tecton Ketone) was given to healthy male Sprague-Dawley (SD) rats 30 minutes prior to glucose administration to determine the blood glucose response to an oral glucose tolerance test (OGTT). Twenty-four SD rats were randomly assigned equally to four groups (two control and two ketone). Blood was analyzed for glucose pre-treatment, before glucose loading at baseline, and at 30, 60, 90 and 120 minutes after glucose loading. Ketone esters at 20 g HED significantly reduced the AUC for blood glucose (by ~21%) compared to glucose-loading control. In this group, the most robust differences occurred at the 30- and 60-minute post ingestion times—with an approximate 50% reduction at 30 minutes post ingestion (p < 0.05) and low variability in response. Although blood ketone levels were not assessed, the preliminary results from this study demonstrate that ketone esters at 20 g HED attenuate the glycemic response to an OGTT in animals, suggesting that ketone esters may one day be promising not only for those with impaired glucose tolerance but also for healthy individuals who seek enhanced glucose regulation. More research is needed in this area, especially in human subjects, to evaluate the generalizability of these findings.